Posts Archive

NCT05509530: Phase 2: Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating RRMM

NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in People With Multiple Myeloma

NCT05204160: Phase 2: Pembrolizumab as Salvage Therapy for Myeloma in Patients Progressing on CAR-T

NCT05182073: Phase 1: FT576 in Subjects With Multiple Myeloma

NCT05396885: Phase 2: Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma - iMMagine-1

NCT05393804: Phase 2: Trial of CART Ide-cel (bb2121) Status Post Hematopoietic cell Transplantation

NCT05347485: Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release

NCT05336383: Phase 2: Phase II Study of Salvage Radiation Treatment After BCMA CART Therapy for RRMM

NCT05257083: Phase 3: EMN 28 - DVRd -> Cilta-Cel (CART) Vs DVRd -> Transplant ASCT- NDMM CARTITUDE-6

NCT05219721: Phase 1: A Study of CAR-GPRC5D in Patients With RRMM Myeloma or Plasma Cell Leukemia

NCT05201781: Phase 4: A Long-term Study for Participants Previously Treated With Cilta-Cel CART

NCT05172596: Phase 2: PHE885 CAR-T Therapy in Adult Participants With Relapsed Refractory Myeloma

NCT05032820: Phase 2: MM CAR-T to Upgrade Response BMT CTN 1902

NCT05066646: Phase 1/2: A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in RRMM

NCT05064787: Evaluating the Feasibility of a Digital Health Coaching Program Post CART

NCT05020444: Phase 1 - TriPRIL CAR T Cells in Multiple Myeloma

NCT05016778: Phase 1: (OriCAR-017) - CAR-T Cells Targeting GPRC5D in the Treatment of RRMM - POLARIS

NCT04816526: Phase 2 - Descartes-08 anti-BCMA-CAR-mRNA-transf. auto CD8+ T cells Consolidation MRD+

NCT04960579: Phase 1: P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Multiple Myeloma